-$P(O)NR^aR^b$, -$P(O)_2NR^aR^b$, -$P(O)OR^a$, -$P(O)_2OR^a$, -CN, or -NO_2; or R^8 and R^9 or R^9 and R^{10} taken together with the carbons to which they are attached form a C_4-C_6 cycloalkyl, a 4- to 7-membered heterocycloalkyl, or a C_6-C_{10} aryl, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_4-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, or 4- to 7-membered heterocycloalkyl is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OR^e, -$OC(O)R^e$, -$OC(O)NR^eR^f$, -$OS(O)R^e$, -$OS(O)_2R^e$, -$OS(O)NR^eR^f$, -$OS(O)_2NR^eR^f$, -SR^e, -$S(O)R^e$, -$S(O)_2R^e$, -$S(O)NR^eR^f$, -$S(O)_2NR^eR^f$, -NR^eR^f, -$NR^eC(O)R^f$, -$NR^eC(O)OR^f$, -$NR^eC(O)NR^eR^f$, -$NR^eS(O)R^f$, -$NR^eS(O)_2R^f$, -$NR^eS(O)NR^eR^f$, -$NR^eS(O)_2NR^eR^f$, -$C(O)R^e$, -$C(O)OR^e$, -$C(O)NR^eR^f$, -PR^eR^f, -$P(O)R^eR^f$, -$P(O)_2R^eR^f$, -$P(O)NR^eR^f$, -$P(O)_2NR^eR^f$, -$P(O)OR^e$, -$P(O)_2OR^e$, -CN, or -NO_2;

[031] each R^a, R^b, R^c, R^d, R^e, and R^f is independently selected from the group consisting of H, deuterium, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, C_1-C_6 alkyl-C_6-C_{10} aryl, and 5- to 10-membered heteroaryl;

[032] m is 0, 1, 2, 3, or 4; and

[033] n is 2, 3, 4, 5, 6, 7, or 8.

[034] In some examples, the disclosure provides a compound of the formula II, or a pharmaceutically acceptable salt thereof,



II

[035] wherein R^1, R^2, A, L, X, X^1, X^2, X^3, X^4, Y, Y^1, Y^2, Z, m and n are as described herein.

[036] In some examples, the disclosure provides a compound of the formula III, or a pharmaceutically acceptable salt thereof,



III

[037] wherein R^1, A, L, X, X^1, X^2, X^3, X^4, Y, Y^2, Z, Z^1, m and n are as described herein.

[038] In some examples, the disclosure provides a compound of the formula IV, or a pharmaceutically acceptable salt thereof,



IV

[039] wherein R^1, R^2, A, L, X, X^1, X^2, X^3, X^4, Y, Y^1, Y^2, Z, m and n are as described herein.

[040] In some examples, the disclosure provides a compound of the formula V, or a pharmaceutically acceptable salt thereof,



V

[041] wherein R^1, A, L, X, X^1, X^2, X^3, X^4, Y, Y^1, Z, Z^1, m and n are as described herein.

[042] In some examples, the disclosure provides a compound of the formula VI, or a pharmaceutically acceptable salt thereof,



VI

[043] wherein R^1, R^2, A, L, X, X^1, X^2, X^3, X^4, Y, Y^1, Y^2, Z, m and n are as described herein.

[044] In some examples, the disclosure provides a compound of the formula VII, or a pharmaceutically acceptable salt thereof,



VII

wherein R^1, R^2, A, B, L, X, X^1, X^2, X^3, X^4, Y, Y^1, Y^2, Z, m and n are as described herein.

[045] In some examples, the disclosure provides a compound of the formula VIII, or a pharmaceutically acceptable salt thereof,



VIII

[046] wherein R^1, R^2, A, B, L, X, X^1, X^2, X^3, X^4, Y, Y^1, Y^2, Z, m and n are as described herein.

[047] In some examples, Ring B (Z) is not , , , , , , or . In some examples, Ring B (Z) is not , or .

[048] In some examples, $C(R^9)$ is H. In some examples, $C(R^9)$ is not –Cl. In some examples, $C(R^{10})$ is H. In some examples, $C(R^{10})$ is not –Cl.

[049] In some examples, the compound is not a compound wherein Ring B (Z) is , , , , , , or , and R^9 and/or R^{10} is not H. In some examples, the compound is not a compound wherein Ring B (Z) is  or , and R^9 and/or R^{10} is not H. In some examples, the compound is not a compound wherein X^1 is $C(R^7)$, X^3 is $C(R^9)$, X^4 is $C(R^{10})$, R^9 and/or R^{10} is not H, and Ring B (Z) is , , , , , , or . In some examples, the compound is not a compound wherein X^1 is $C(R^7)$, X^3 is $C(R^9)$, X^4 is $C(R^{10})$, R^9 and/or R^{10} is not H, and Ring B (Z) is  or . In some examples, the compound is not a compound wherein X^1 is $C(R^7)$, X^3 is $C(R^9)$, X^4 is $C(R^{10})$, R^9 and/or R^{10} is –Cl, and Ring B (Z) is , , , , , , , or . In some examples, the compound is not a compound wherein X^1 is $C(R^7)$, X^3 is $C(R^9)$, X^4 is $C(R^{10})$, R^9 and/or R^{10} is–Cl, and Ring B (Z)

is , or . In some examples, X^1 is $C(R^7)$, X^3 is $C(R^9)$, X^4 is $C(R^{10})$, and R^9 and/or R^{10} is not –Cl. In some examples, X^1 is $C(R^7)$, X^3 is $C(R^9)$, X^4 is $C(R^{10})$, R^9 and/or R^{10} is not –Cl, and Ring B (Z) is not , , , , , , or . In some examples, X^1 is $C(R^7)$, X^3 is $C(R^9)$, X^4 is $C(R^{10})$, R^9 and/or R^{10} is not –Cl, and Ring B (Z) is not  or .

[050] In certain examples, the compound of Formula (I)-(VIII) is a compound selected from those species described or exemplified in the detailed description below.

[051] In further examples, the disclosure relates to a pharmaceutical composition comprising at least one compound of Formula (I)-(VIII) or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions according to the disclosure may further comprise a pharmaceutically acceptable excipient.

[051a] In another aspect, there is provided a pharmaceutical composition comprising at least one compound as defined above, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable excipients.

[052] In further examples, the disclosure relates to a compound of Formula (I)-(VIII), or a pharmaceutically acceptable salt thereof, for use as a medicament.

[053] In further examples, the disclosure relates to a method of treating disease, such as cancer comprising administering to a subject in need of such treatment an effective amount of at least one compound of Formula (I)-(VIII), or a pharmaceutically acceptable salt thereof.

[053a] In another aspect, there is provided the use of a compound as defined above, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating autoimmune diseases in a subject.

[054] In further examples, the disclosure relates to use of a compound of Formula (I)-(VIII), or a a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of disease, such as cancer, and the use of such compounds and salts for treatment of such diseases.

[055] In further examples, the disclosure relates to a method of inhibiting a tyrosine kinase, such as EGFR, comprising contacting a cell comprising one or more of kinase with an effective amount of at least one compound of Formula (I)-(VIII), or a a pharmaceutically acceptable salt

thereof, and/or with at least one pharmaceutical composition of the disclosure, wherein the contacting is *in vitro, ex vivo,* or *in vivo*.

[056] Additional examples, features, and advantages of the disclosure will be apparent from the following detailed description and through practice of the disclosure. The compounds of the present disclosure can be described as examples in any of the following enumerated clauses. It will be understood that any of the examples described herein can be used in connection with any other examples described herein to the extent that the examples do not contradict one another.

[057] 1. A compound of the formula I, or a pharmaceutically acceptable salt thereof,



I

[058] wherein

[059] A is a 5- to 10-membered heteroarylene or C_6-C_{10} arylene;

[060] each L is independently -C(R^3)(R^4)-, -C(O)-, -O-, -N(R^5)-, -S-, -S(O)- or -S(O)$_2$-, provided that $(L)_n$ does not comprise a –O-O-, a –O-S-, or a –O-N(R^5)- bond;

[061] X is N or C(R^6);

[062] X^1 is N or C(R^7);

[063] X^2 is N or C(R^8);

[064] X^3 is N or C(R^9);

[065] X^4 is N or C(R^{10});

[066] Y and Y^1 are each independently O or S;

[067] Y^2 is -O-, -N(R^{11})-, or -S-;

[068] Z is a 3- to 7-membered heterocycloalkylene, C_3-C_6 cycloalkylene, C_6-C_{10} arylene, 5- to 10-membered heteroarylene, -C(R^{12})(R^{13})-, -C(O)-, -O-, -N(R^{14})-, -S-, -S(O)- or -S(O)$_2$-, wherein each hydrogen atom in 3- to 7-membered heterocycloalkylene, C_3-C_6 cycloalkylene, C_6-C_{10} arylene, and 5- to 10-membered heteroarylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, -OR^e, -OC(O)R^e, -OC(O)N$R^e R^f$, -OS(O)R^e, -OS(O)$_2R^e$, -OS(O)N$R^e R^f$, -OS(O)$_2$N$R^e R^f$, -SR^e, -S(O)R^e, -S(O)$_2R^e$, -S(O)N$R^e R^f$,

WHAT IS CLAIMED IS:

1. A compound of the formula I, or a pharmaceutically acceptable salt thereof,



I

wherein

A is a 5- to 10-membered heteroarylene or C_6-C_{10} arylene;

each L is independently -C(R^3)(R^4)-, -C(O)-, -O-, -N(R^5)-, -S-, -S(O)- or -S(O)$_2$-, provided that $(L)_n$ does not comprise a –O-O-, a –O-S-, or a –O-N(R^5)- bond;

X is N or C(R^6);

X^1 is N or C(R^7);

X^2 is N or C(R^8);

X^3 is N or C(R^9);

X^4 is N or C(R^{10});

Y and Y^1 are each independently O or S;

Y^2 is -O-, -N(R^{11})-, or -S-;

Z is a 3- to 7-membered heterocycloalkylene, C_3-C_6 cycloalkylene, C_6-C_{10} arylene, 5- to 10-membered heteroarylene, -C(R^{12})(R^{13})-, -C(O)-, -O-, -N(R^{14})-, -S-, -S(O)- or -S(O)$_2$-, wherein each hydrogen atom in 3- to 7-membered heterocycloalkylene, C_3-C_6 cycloalkylene, C_6-C_{10} arylene, and 5- to 10-membered heteroarylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, -OR^e, -OC(O)R^e, -OC(O)N$R^e$$R^f$, -OS(O)$R^e$, -OS(O)$_2$$R^e$, -OS(O)N$R^e$$R^f$, -OS(O)$_2NR^e$$R^f$, -$SR^e$, -S(O)$R^e$, -S(O)$_2$$R^e$, -S(O)N$R^e$$R^f$, -S(O)$_2NR^e$$R^f$, -N$R^e$$R^f$, -N$R^e$C(O)$R^f$, -N$R^e$C(O)O$R^f$, -N$R^e$C(O)N$R^e$$R^f$, -N$R^e$S(O)$R^f$, -N$R^e$S(O)$_2$$R^f$, -N$R^e$S(O)N$R^e$$R^f$, -N$R^e$S(O)$_2NR^e$$R^f$, -C(O)$R^e$, -C(O)O$R^e$, -C(O)N$R^e$$R^f$, -P$R^e$$R^f$, -P(O)$R^e$$R^f$, -P(O)$_2$$R^e$$R^f$, -P(O)N$R^e$$R^f$, -P(O)$_2NR^e$$R^f$, -P(O)O$R^e$, -P(O)$_2OR^e$, -CN, or -NO$_2$;

Z^1 is –NR^2C(Y^1)-, –C(Y^1)NR^2-, -O-, -N(R^2)-, -S-, -S(O)- or -S(O)$_2$-,

each R^1 is independently deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered

heteroaryl, $-OR^a$, $-OC(O)R^a$, $-OC(O)NR^aR^b$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-OS(O)NR^aR^b$, $-OS(O)_2NR^aR^b$, $-NR^aR^b$, $-NR^aC(O)R^b$, $-NR^aC(O)OR^b$, $-NR^aC(O)NR^aR^b$, $-NR^aS(O)R^b$, $-NR^aS(O)_2R^b$, $-NR^aS(O)NR^aR^b$, $-NR^aS(O)_2NR^aR^b$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^aR^b$, $-PR^aR^b$, $-P(O)R^aR^b$, $-P(O)_2R^aR^b$, $-P(O)NR^aR^b$, $-P(O)_2NR^aR^b$, $-P(O)OR^a$, $-P(O)_2OR^a$, -CN, or $-NO_2$, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl, is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^e$, -CN, or $-NO_2$;

each of R^2, $R^{5,}$ R^{11}, or R^{14} is independently H, deuterium, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^{e'}$, -CN, or $-NO_2$;

each R^3, R^4, R^{12} and R^{13} is independently H, deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, $-OR^c$, $-OC(O)R^c$, $-OC(O)NR^cR^d$, $-OC(=N)NR^cR^d$, $-OS(O)R^c$, $-OS(O)_2R^c$, $-OS(O)NR^cR^d$, $-OS(O)_2NR^cR^d$, $-SR^c$, $-S(O)R^c$, $-S(O)_2R^c$, $-S(O)NR^cR^d$, $-S(O)_2NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^d$, $-N(C(O)R^c)(C(O)R^d)$, $-NR^cC(O)OR^d$, $-NR^cC(O)NR^cR^d$, $-NR^cC(=N)NR^cR^d$, $-NR^cS(O)R^d$, $-NR^cS(O)_2R^d$, $-NR^cS(O)NR^cR^d$, $-NR^cS(O)_2NR^cR^d$, $-C(O)R^c$, $-C(O)OR^c$, $-C(O)NR^cR^d$, $-C(=N)NR^cR^d$, $-PR^cR^d$, $-P(O)R^cR^d$, $-P(O)_2R^cR^d$, $-P(O)NR^cR^d$, $-P(O)_2NR^cR^d$, $-P(O)OR^c$, $-P(O)_2OR^c$, -CN, $-NO_2$, or two of R^3, R^4, R^{12}, and R^{13} taken together with the carbon or carbons to which they are attached form a C_3-C_6 cycloalkyl or a 4- to 6-membered heterocycloalkyl, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, or 4- to 6-membered heterocycloalkyl is independently optionally

substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OR^e, -$OC(O)R^e$, -$OC(O)NR^eR^f$, -$OS(O)R^e$, -$OS(O)_2R^e$, -$OS(O)NR^eR^f$, -$OS(O)_2NR^eR^f$, -SR^e, -$S(O)R^e$, -$S(O)_2R^e$, -$S(O)NR^eR^f$, -$S(O)_2NR^eR^f$, -NR^eR^f, -$NR^eC(O)R^f$, -$NR^eC(O)OR^f$, -$NR^eC(O)NR^eR^f$, -$NR^eS(O)R^f$, -$NR^eS(O)_2R^f$, -$NR^eS(O)NR^eR^f$, -$NR^eS(O)_2NR^eR^f$, -$C(O)R^e$, -$C(O)OR^e$, -$C(O)NR^eR^f$, -PR^eR^f, -$P(O)R^eR^f$, -$P(O)_2R^eR^f$, -$P(O)NR^eR^f$, -$P(O)_2NR^eR^f$, -$P(O)OR^e$, -$P(O)_2OR^e$, -CN, or -NO_2;

R^6 is H, deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, or –CN;

each of R^7 and R^8 is independently a bond to Z, H, deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, -OR^a, -$OC(O)R^a$, -$OC(O)NR^aR^b$, -$OS(O)R^a$, -$OS(O)_2R^a$, -SR^a, -$S(O)R^a$, -$S(O)_2R^a$, -$S(O)NR^aR^b$, -$S(O)_2NR^aR^b$, -$OS(O)NR^aR^b$, -$OS(O)_2NR^aR^b$, -NR^aR^b, -$NR^aC(O)R^b$, -$NR^aC(O)OR^b$, -$NR^aC(O)NR^aR^b$, -$NR^aS(O)R^b$, -$NR^aS(O)_2R^b$, -$NR^aS(O)NR^aR^b$, -$NR^aS(O)_2NR^aR^b$, -$C(O)R^a$, -$C(O)OR^a$, -$C(O)NR^aR^b$, -PR^aR^b, -$P(O)R^aR^b$, -$P(O)_2R^aR^b$, -$P(O)NR^aR^b$, -$P(O)_2NR^aR^b$, -$P(O)OR^a$, -$P(O)_2OR^a$, -CN, or -NO_2; wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl, is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OR^e, -$OC(O)R^e$, -$OC(O)NR^eR^f$, -$OS(O)R^e$, -$OS(O)_2R^e$, -$OS(O)NR^eR^f$, -$OS(O)_2NR^eR^f$, -SR^e, -$S(O)R^e$, -$S(O)_2R^e$, -$S(O)NR^eR^f$, -$S(O)_2NR^eR^f$, -NR^eR^f, -$NR^eC(O)R^f$, -$NR^eC(O)OR^f$, -$NR^eC(O)NR^eR^f$, -$NR^eS(O)R^f$, -$NR^eS(O)_2R^f$, -$NR^eS(O)NR^eR^f$, -$NR^eS(O)_2NR^eR^f$, -$C(O)R^e$, -$C(O)OR^e$, -$C(O)NR^eR^f$, -PR^eR^f, -$P(O)R^eR^f$, -$P(O)_2R^eR^f$, -$P(O)NR^eR^f$, -$P(O)_2NR^eR^f$, -$P(O)OR^e$, -$P(O)_2OR^e$, -CN, or -NO_2; provided that one of R^7 or R^8 is a bond to Z;

each of R^9 and R^{10} is independently H, deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, -OR^a, -$OC(O)R^a$, -$OC(O)NR^aR^b$, -$OS(O)R^a$, -$OS(O)_2R^a$, -SR^a, -$S(O)R^a$, -$S(O)_2R^a$, -$S(O)NR^aR^b$, -$S(O)_2NR^aR^b$, -$OS(O)NR^aR^b$, -$OS(O)_2NR^aR^b$, -NR^aR^b, -$NR^aC(O)R^b$, -$NR^aC(O)OR^b$, -$NR^aC(O)NR^aR^b$, -$NR^aS(O)R^b$, -$NR^aS(O)_2R^b$, -$NR^aS(O)NR^aR^b$, -$NR^aS(O)_2NR^aR^b$, -$C(O)R^a$, -$C(O)OR^a$, -$C(O)NR^aR^b$, -PR^aR^b, -$P(O)R^aR^b$, -$P(O)_2R^aR^b$, -$P(O)NR^aR^b$, -$P(O)_2NR^aR^b$, -$P(O)OR^a$, -$P(O)_2OR^a$, -CN, or -NO_2; or R^8 and R^9 or R^9 and R^{10} taken together with the carbons to which they are attached form a C_4-C_6 cycloalkyl, a 4- to 7-membered heterocycloalkyl, or a C_6-C_{10} aryl, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_4-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, or 4- to 7-membered heterocycloalkyl is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OR^e, -$OC(O)R^e$, -$OC(O)NR^eR^f$, -$OS(O)R^e$, -$OS(O)_2R^e$, -$OS(O)NR^eR^f$,

$-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^e$, -CN, or $-NO_2$;

each R^a, R^b, R^c, R^d, R^e, and R^f is independently selected from the group consisting of H, deuterium, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, C_1-C_6 alkyl-C_6-C_{10} aryl, and 5- to 10-membered heteroaryl;

m is 0, 1, 2, 3, or 4; and

n is 2, 3, 4, 5, 6, 7, or 8.

2. The compound of claim 1 having the formula IV



IV

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein A is phenylene, furanylene, thiophenylene, pyrrolylene, oxazolylene, isoxazolylene, thiazolylene, isothiazolylene, pyrazolylene, imidazolylene, oxadiazolylene, thiadiazolylene, triazolylene, pyridinylene, pyrazinylene, pyrimidinylene, pyridazinylene, or triazinylene.

4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein A is , , or , wherein R^{1a} is C_1-C_6 alkyl, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^aR^b$, or $-P(O)_2OR^a$, wherein each hydrogen atom in C_1-C_6 alkyl is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl,

C_1-C_6 haloalkyl, -OR^e, -$OC(O)R^e$, -$OC(O)NR^eR^f$, -$OS(O)R^e$, -$OS(O)_2R^e$, -$OS(O)NR^eR^f$, -$OS(O)_2NR^eR^f$, -SR^e, -$S(O)R^e$, -$S(O)_2R^e$, -$S(O)NR^eR^f$, -$S(O)_2NR^eR^f$, -NR^eR^f, -$NR^eC(O)R^f$, -$NR^eC(O)OR^f$, -$NR^eC(O)NR^eR^f$, -$NR^eS(O)R^f$, -$NR^eS(O)_2R^f$, -$NR^eS(O)NR^eR^f$, -$NR^eS(O)_2NR^eR^f$, -$C(O)R^e$, -$C(O)OR^e$, -$C(O)NR^eR^f$, -PR^eR^f, -$P(O)R^eR^f$, -$P(O)_2R^eR^f$, -$P(O)NR^eR^f$, -$P(O)_2NR^eR^f$, -$P(O)OR^e$, -$P(O)_2OR^e$, -CN, or -NO_2.

5. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^2 is H or C_1-C_6 alkyl, wherein each hydrogen atom in C_1-C_6 alkyl is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OR^e, -$OC(O)R^e$, -$OC(O)NR^eR^f$, -$OS(O)R^e$, -$OS(O)_2R^e$, -$OS(O)NR^eR^f$, -$OS(O)_2NR^eR^f$, -SR^e, -$S(O)R^e$, -$S(O)_2R^e$, -$S(O)NR^eR^f$, -$S(O)_2NR^eR^f$, -NR^eR^f, -$NR^eC(O)R^f$, -$NR^eC(O)OR^f$, -$NR^eC(O)NR^eR^f$, -$NR^eS(O)R^f$, -$NR^eS(O)_2R^f$, -$NR^eS(O)NR^eR^f$, -$NR^eS(O)_2NR^eR^f$, -$C(O)R^e$, -$C(O)OR^e$, -$C(O)NR^eR^f$, -PR^eR^f, -$P(O)R^eR^f$, -$P(O)_2R^eR^f$, -$P(O)NR^eR^f$, -$P(O)_2NR^eR^f$, -$P(O)OR^e$, -$P(O)_2OR^{e'}$, -CN, or -NO_2.

6. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Z is pyrazolylene, oxazolylene, thiazolylene, pyridinylene, pyrimidinylene, or pyridin-2-onylene, wherein each hydrogen atom in pyrazolylene, oxazolylene, thiazolylene, pyridinylene, pyrimidinylene, and pyridin-2-onylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OR^e, -$OC(O)R^e$, -$OC(O)NR^eR^f$, -$OS(O)R^e$, -$OS(O)_2R^e$, -$OS(O)NR^eR^f$, -$OS(O)_2NR^eR^f$, -SR^e, -$S(O)R^e$, -$S(O)_2R^e$, -$S(O)NR^eR^f$, -$S(O)_2NR^eR^f$, -NR^eR^f, -$NR^eC(O)R^f$, -$NR^eC(O)OR^f$, -$NR^eC(O)NR^eR^f$, -$NR^eS(O)R^f$, -$NR^eS(O)_2R^f$, -$NR^eS(O)NR^eR^f$, -$NR^eS(O)_2NR^eR^f$, -$C(O)R^e$, -$C(O)OR^e$, -$C(O)NR^eR^f$, -PR^eR^f, -$P(O)R^eR^f$, -$P(O)_2R^eR^f$, -$P(O)NR^eR^f$, -$P(O)_2NR^eR^f$, -$P(O)OR^e$, -$P(O)_2OR^e$, -CN, or -NO_2.

7. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein n is 5.

8. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein each L is independently selected from the group consisting of -C(O)-, -O-, -CH_2-, -C(H)(CH_3)-, -C(H)(OH)-, -C(H)(C(O)OR^c)-, -C(H)(C(O)NR^cR^d)-, -NH-, and -NCH_3-.

9. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein X is C(R^6).

10. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Y is O.

11. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Y^1 is O.

12. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Y^2 is $–N(R^{11})-$.

13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein X^1 is $C(R^7)$, X^3 is $C(R^9)$, and X^4 is $C(R^{10})$.

14. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein $–(L)_n-$ is $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-(CH_2)_5-$, $-(CH_2)_6-$, $-C(O)NH-(CH_2)_2O(CH_2)_2-$, $-C(O)N(CH_3)-(CH_2)_2O(CH_2)_2-$, $-NHC(O)CH_2O(CH_2)_2-$, $-N(CH_3)-C(O)CH_2O(CH_2)_2-$, $-CH_2O(CH_2)_2-$, $-(CH_2)_2O(CH_2)_2-$, $-(CH_2)_2S(CH_2)_2-$, $-O(CH_2)_2S(CH_2)_2-$, $-(CH_2)_2SO_2(CH_2)_2-$, $-O(CH_2)_2SO_2(CH_2)_2-$, $-(CH_2)_2SO(CH_2)_2-$, $-O(CH_2)_2SO(CH_2)_2-$, $-(CH_2)_2O(C(H)(C(O)N(H)$ (azetidin-3-yl))$-CH_2-$, $-(CH_2)_2O(C(H)(C(O)N(H)(CH_3))-CH_2-$, $-(CH_2)_2O(C(H)(C(O)N(CH_3)_2)-CH_2-$, $-(CH_2)_2O(C(H)(C(O)N(H)$(piperidin-4-yl))$-CH_2-$, $-(CH_2)_2O(C(H)(C(O)N(H)$(pyrrolidin-3-yl))$-CH_2-$, $-(CH_2)_2O(C(H)(C(O)N(H)$(4-methylpiperazin-1-yl))$-CH_2-$, $-(CH_2)_2O(C(H)(C(O)OCH_3)-CH_2-$, $-(CH_2)_3O(CH_2)_2-$, $-(CH_2)_2O(CH_2)_3-$, $-CH_2CH(CH_3)-O(CH_2)_2-$, $-CH(CH_3)-CH_2O(CH_2)_2-$, $-O(CH_2)_2-$, $-O-(CH_2)_3-$, $-OCH_2O(CH_2)_2-$, $-O-CH_2CH(OH)CH_2-$, $-O-(CH_2)_2O(CH_2)_2-$, $-O-CH_2CH(CH_3)-O(CH_2)_2-$, $-O-CH(CH_3)-CH_2O(CH_2)_2-$, $-O-(CH_2)_2NH-(CH_2)_2-$, $-O-CH_2CH(CH_3)-NH-(CH_2)_2-$, $-O-CH(CH_3)-CH_2NH-(CH_2)_2-$, $-CH_2NH-(CH_2)_2-$, $-(CH_2)_2NH-(CH_2)_2-$, $-CH_2CH(CH_3)-NH-(CH_2)_2-$, $-CH(CH_3)-CH_2NH-(CH_2)_2-$, $-O-(CH_2)_2N(CH_3)-(CH_2)_2-$, $-O-CH_2CH(CH_3)-N(CH_3)-(CH_2)_2-$, $-O-CH(CH_3)-CH_2N(CH_3)-(CH_2)_2-$, $-CH_2N(CH_3)-(CH_2)_2-$, $-CH_2N(CH_2CH_3)-(CH_2)_2-$, $-CH_2N(CH(CH_3))-(CH_2)_2-$, $-(CH_2)_2N(CH_3)-(CH_2)_2-$, $-CH_2CH(CH_3)-N(CH_3)-(CH_2)_2-$, or $-O-CH(CH_3)-CH_2N(CH_3)-(CH_2)_2-$.

15. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of [3a(4)*Z*]-10,11-dihydro-2*H*,13*H*-16,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]oxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-9,10,11,12-tetrahydro-14*H*-17,1-(azenometheno)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,10,11,12-tetrahydro-14*H*-1,17-(azenometheno)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,10,11,12-tetrahydro-14*H*-1,17-(diazanediylidene)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,10,11,12-tetrahydro-14*H*-17,1-(azenometheno)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,10,11,12-tetrahydro-14*H*-1,17-(azenometheno)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*,11*S*]-11-hydroxy-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[19a(20)*Z*]-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*,12*H*-15,17-(ethanediylidene)pyrazolo[4,3-*p*]dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7,14]dioxadiazacycloheptadecine-4,19(5*H*,18*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-3,8-dioxo-2,3,5,8,9,10,11,12-octahydro-14*H*-1,17-(ethanediylidene)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-6-carbonitrile;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)imidazo[4,5-*i*]pyrazolo[3,4-*b*]pyrrolo[3,4-*f*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,15-dimethyl-9,10,11,12-tetrahydro-15*H*-1,17-(ethanediylidene)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-1,17-(ethanediylidene)[1,2]oxazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,16-dimethyl-9,10,11,12-tetrahydro-1,17-(ethanediylidene)[1,2]oxazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-1,17-(ethanediylidene)dipyrrolo[3,4-*f*:2',3'-*i*][1,2]thiazolo[3,4-*b*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9-dimethyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9-dimethyl-9,10,11,12-tetrahydro-1,17-(ethanediylidene)[1,2]oxazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9,16-trimethyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9,16-trimethyl-9,10,11,12-tetrahydro-1,17-(ethanediylidene)[1,2]oxazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-1,17-(ethanediylidene)pyrazolo[5,1-*c*]dipyrrolo[3,2-*j*:3',4'-*m*][1,4,8]triazacyclotetradecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-17,1-(azenometheno)pyrazolo[1,5-*e*]dipyrrolo[3,4-*i*:2',3'-*l*][1,5]diazacyclotetradecine-3,8(2*H*,5*H*)-dione;
[19a(20)*Z*]-2-methyl-6,7,9,10-tetrahydro-1*H*-15,17-(ethanediylidene)pyrazolo[1,5-*d*]dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,19(5*H*,18*H*)-dione;
[19a(20)*Z*]-2-methyl-6,7,9,10-tetrahydro-1*H*-15,17-(azenometheno)pyrazolo[1,5-*d*]dipyrrolo[3,4-*h*:2',3'-*k*][1,4,14]oxadiazacyclohexadecine-4,19(5*H*,18*H*)-dione;
[19a(20)*Z*]-2-methyl-6,7,9,10-tetrahydro-1*H*-15,17-(azenometheno)pyrazolo[1,5-*d*]dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,19(5*H*,18*H*)-dione;
[19a(20)*Z*]-2-methyl-6,7,9,10-tetrahydro-1*H*-15,17-(ethanediylidene)pyrazolo[1,5-*d*]dipyrrolo[3,4-*h*:2',3'-*k*][1,4,14]oxadiazacyclohexadecine-4,19(5*H*,18*H*)-dione;
[10*R*,19a(20)*Z*]-2,10-dimethyl-6,7,9,10-tetrahydro-1*H*-15,17-(ethanediylidene)pyrazolo[1,5-*d*]dipyrrolo[3,4-*h*:2',3'-*k*][1,4,14]oxadiazacyclohexadecine-4,19(5*H*,18*H*)-dione;
[19a(20)*Z*]-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*-15,17-(ethanediylidene)pyrazolo[1,5-*d*]dipyrrolo[3,4-*h*:2',3'-*k*][1,4,14]oxadiazacyclohexadecine-4,19(5*H*,18*H*)-dione;
[19a(20)*Z*]-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*-15,17-(azenometheno)pyrazolo[1,5-*d*]dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,19(5*H*,18*H*)-dione;
[19a(20)*Z*]-2-methyl-5,6,7,8,9,10-hexahydro-15,17-(ethanediylidene)pyrazolo[1,5-*g*]dipyrrolo[3,4-*k*:2',3'-*n*][1,4,7]triazacyclohexadecine-4,19(1*H*,18*H*)-dione;
[19a(20)*Z*]-2,5-dimethyl-5,6,7,8,9,10-hexahydro-15,17-(ethanediylidene)pyrazolo[1,5-*g*]dipyrrolo[3,4-*k*:2',3'-*n*][1,4,7]triazacyclohexadecine-4,19(1*H*,18*H*)-dione;
[3a(4)*Z*]-6-methyl-10,11,13,14-tetrahydro-2*H*-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]oxadiazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6-methyl-10,11,13,14-tetrahydro-2*H*-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6-methyl-10,11,13,14-tetrahydro-2*H*-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-6,9-dimethyl-10,11,13,14-tetrahydro-2*H*-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6,9,16-trimethyl-10,11,13,14-tetrahydro-2*H*-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9-dimethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9-dimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9-dimethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9-dimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-20-fluoro-6,9-dimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-19-fluoro-6,9-dimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9,20-trimethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,20-dimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,16-dimethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9,16-trimethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-16-cyclopropyl-6,9-dimethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-16-cyclopropyl-6,9-dimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9,16-trimethyl-10,11,12,13-tetrahydro-2*H*-17,1-(azenometheno)[1,2]oxazolo[4,5-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-6,9,16-trimethyl-10,11,12,13-tetrahydro-2*H*-17,1-(azenometheno)[1,2]oxazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-6,14-dimethyl-10,11,13,14-tetrahydro-2*H*-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-6,9,14-trimethyl-10,11,13,14-tetrahydro-2*H*-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-6,9,14-trimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9,12,14-tetramethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9,16-trimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9,16-trimethyl-10,11-dihydro-2*H*,13*H*-1,17-(ethanediylidene)[1,2]oxazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-6,9,16-trimethyl-10,11,12,13-tetrahydro-2*H*-1,17-(ethanediylidene)[1,2]oxazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-6,9,12,14,16-pentamethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9,14,16-tetramethyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9,14,16-tetramethyl-10,11,13,14-tetrahydro-2*H*-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-9,14,16-trimethyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-9,14,16-trimethyl-10,11,13,14-tetrahydro-2*H*-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-12-ethyl-6,9,14-trimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9,14-trimethyl-12-(propan-2-yl)-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-16-cyclopropyl-6,9-dimethyl-10,11-dihydro-2*H*,13*H*-1,17-(ethanediylidene)[1,2]oxazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-9,14-dimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9-dimethyl-16-(propan-2-yl)-10,11-dihydro-2*H*,13*H*-1,17-(ethanediylidene)[1,2]oxazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-9-methyl-16-(propan-2-yl)-10,11-dihydro-2*H*,13*H*-1,17-(ethanediylidene)[1,2]oxazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6,9,14-trimethyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,14-dimethyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9,12,14-tetramethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,12,14-trimethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9,12,14-tetramethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione; and
[3a(4)*Z*]-9,12,14-trimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione.

16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of [3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-1,18-(ethanediylidene)dipyrrolo[3,2-*g*:3',4'-*j*][1,5,12]benzoxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6-methyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]benzoxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6-methyl-10,11-dihydro-2*H*-17,1-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4]benzoxazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-16-fluoro-6-methyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]benzoxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-15-fluoro-6-methyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]benzoxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-14-fluoro-6-methyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]benzoxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-13-fluoro-6-methyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]benzoxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione; and
[3a(4)*Z*]-6,9,12-trimethyl-10,11,12,13-tetrahydro-2*H*-1,18-(ethanediylidene)dipyrrolo[3,2-*g*:3',4'-*j*][2,5]benzodiazacyclopentadecine-3,8(5*H*,9*H*)-dione.

17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of [3a(4)*Z*]-6-methyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)pyrido[3,2-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]oxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6-methyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)pyrimido[5,4-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]oxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6,16-dimethyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)pyrido[3,4-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]oxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-14*H*-1,18-(ethanediylidene)pyrido[2,1-*c*]dipyrrolo[3,2-*j*:3',4'-*m*][1,4,8]triazacyclotetradecine-3,8,14(2*H*,5*H*)-trione;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-14*H*-18,1-(azenometheno)pyrido[1,2-*e*]dipyrrolo[3,4-*i*:2',3'-*l*][1,5]diazacyclotetradecine-3,8,14(2*H*,5*H*)-trione;
or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of [3a(4)*Z*,13a*R*]-6-methyl-10,11,12,13,13a,14,15,16-octahydro-2*H*-

18,1-(azenometheno)tripyrrolo[1,2-*a*:3',2'-*i*:3",4"-*l*][1,4,7]triazacyclopentadecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*,13a*R*]-6-methyl-9,10,11,12,13,13a,14,15-octahydro-17,1-(azenometheno)azeto[1,2-*a*]dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]triazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[16a(17)*Z*]-2,11-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-12,14-(azenometheno)dipyrrolo[3,4-*g*:2',3'-*j*][1,4,6,13]oxatriazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-2,5,11-trimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-12,14-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,13]oxadiazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[17a(18)*Z*]-2,12-dimethyl-6,7,9,10,11,12-hexahydro-1*H*-13,15-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,13]oxadiazacyclohexadecine-4,17(5*H*,16*H*)-dione;

[17a(18)*Z*]-2,5,12-trimethyl-6,7,9,10,11,12-hexahydro-1*H*-13,15-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,13]oxadiazacyclohexadecine-4,17(5*H*,16*H*)-dione;

[17a(18)*Z*]-2,5,12-trimethyl-6,7,9,10,11,12-hexahydro-1*H*-13,15-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11,13]oxatriazacyclohexadecine-4,17(5*H*,16*H*)-dione;

[16a(17)*Z*]-2,5,11-trimethyl-6,7,8,9,10,11-hexahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]triazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-2,5,11-trimethyl-6,7,8,9,10,11-hexahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*k*:3',4'-*n*][1,3,6,9]tetraazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-2,5,11-trimethyl-6,7,8,9,10,11-hexahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,2-*k*:3',4'-*n*][1,3,6,9]tetraazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-11-cyclopropyl-2,5-dimethyl-6,7,8,9,10,11-hexahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*k*:3',4'-*n*][1,3,6,9]tetraazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-11-cyclopropyl-2-methyl-6,7,8,9,10,11-hexahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,2-*k*:3',4'-*n*][1,3,6,9]tetraazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*R*,16a(17)*Z*]-2,5,10-trimethyl-6,7,8,9,10,11-hexahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]triazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,8,9,10,11-hexahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]triazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-12,14-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,13]oxadiazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-12,14-(azenometheno)dipyrrolo[3,4-*g*:2',3'-*j*][1,4,6,13]oxatriazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,4-*d*:2',3'-*g*][1,13,3,10]dioxadiazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,4-*d*:2',3'-*g*][1,13,3,10]dioxadiazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[10*S*,16a(17)*Z*]-2,5,10-trimethyl-5,6,7,8,9,10-hexahydro-12,14-(azenometheno)dipyrrolo[3,4-*d*:2',3'-*g*][1,3,10,13]oxatriazacyclopentadecine-4,16(1*H*,15*H*)-dione;
[10*S*,16a(17)*Z*]-2,5,10-trimethyl-5,6,7,8,9,10-hexahydro-12,14-(ethanediylidene)dipyrrolo[3,4-*d*:2',3'-*g*][1,3,10,13]oxatriazacyclopentadecine-4,16(1*H*,15*H*)-dione;
[10*S*,16a(17)*Z*]-2,5,10-trimethyl-5,6,7,8,9,10-hexahydro-12,14-(azenometheno)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxadiazacyclopentadecine-4,16(1*H*,15*H*)-dione;
[9*R*,16a(17)*Z*]-2,5,9-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,4-*d*:2',3'-*g*][1,13,3,10]dioxadiazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[9*S*,16a(17)*Z*]-2,5,9-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,4-*d*:2',3'-*g*][1,13,3,10]dioxadiazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[16a(17)*Z*]-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[10*R*,16a(17)*Z*]-2,5,10-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[10*S*,16a(17)*Z*]-2,10-dimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-5,6,7,8,9,10-hexahydro-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxadiazacyclopentadecine-4,16(1*H*,15*H*)-dione;

[9*R*,16a(17)*Z*]-2,5,9-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[9*S*,16a(17)*Z*]-2,5,9-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[17a(18)*Z*]-2-methyl-6,7,10,11-tetrahydro-1*H*,9*H*-13,15-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,13,4]oxathiazacyclohexadecine-4,17(5*H*,16*H*)-dione;

[17a(18)*Z*]-2-methyl-6,7,10,11-tetrahydro-1*H*-13,15-(ethanediylidene)-12λ^6-dipyrrolo[3,2-*f*:3',4'-*i*][1,13,4]oxathiazacyclohexadecine-4,12,12,17(5*H*,9*H*,16*H*)-tetrone;

[17a(18)*Z*]-2-methyl-6,7,9,10-tetrahydro-1*H*,12*H*-13,15-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclohexadecine-4,17(5*H*,16*H*)-dione;

[12*R*,17a(18)*Z*]-2,12-dimethyl-6,7,9,10-tetrahydro-1*H*,12*H*-13,15-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclohexadecine-4,17(5*H*,16*H*)-dione;

[12*S*,17a(18)*Z*]-2,12-dimethyl-6,7,9,10-tetrahydro-1*H*,12*H*-13,15-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclohexadecine-4,17(5*H*,16*H*)-dione;

[12*S*,17a(18)*Z*]-2,5,12-trimethyl-6,7,9,10-tetrahydro-1*H*,12*H*-13,15-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclohexadecine-4,17(5*H*,16*H*)-dione;

[17a(18)*Z*]-2,5-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,14]oxadiazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;

[17a(18)*Z*]-2,5-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(azenometheno)dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;

[17a(18)*Z*]-2,5-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,14]oxadiazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;

[17a(18)*Z*]-2,5-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(ethanediylidene)dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;

[12*S*,17a(18)*Z*]-2,5,12-trimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(ethanediylidene)dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;

[17a(18)*Z*]-2-methyl-6,7,11,12-tetrahydro-1*H*-13,15-(ethanediylidene)dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;

[17a(18)*Z*]-2,11-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(ethanediylidene)dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;

[17a(18)*Z*]-2,11-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,14]oxadiazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;
[17a(18)*Z*]-2,11-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(azenometheno)dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;
[17a(18)*Z*]-2,11-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,14]oxadiazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;
[18a(19)*Z*]-2-methyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,15]oxadiazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[18a(19)*Z*]-2,5-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,15]oxadiazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[18a(19)*Z*]-2,11-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,15]oxadiazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[13*S*,18a(19)*Z*]-2,13-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,15]oxadiazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[13*R*,18a(19)*Z*]-2,13-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,15]oxadiazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[18a(19)*Z*]-2-methyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(azenometheno)dipyrrolo[3,4-*i*:2',3'-*l*][1,4,8,15]oxatriazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[13*S*,18a(19)*Z*]-2,13-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(ethanediylidene)dipyrrolo[3,4-*i*:2',3'-*l*][1,4,8,15]oxatriazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[13*S*,18a(19)*Z*]-2,13-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,15]oxadiazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[13*S*,18a(19)*Z*]-13-hydroxy-2,13-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,15]oxadiazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[16a(17)*Z*]-2-methyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[16a(17)*Z*]-19-chloro-2-methyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[16a(17)*Z*]-19-chloro-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

methyl [7*R*,16a(17)*Z*]-19-chloro-2,5-dimethyl-4,16-dioxo-4,5,6,7,9,10,15,16-octahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-7-carboxylate;
[7*R*,16a(17)*Z*]-*N*-(azetidin-3-yl)-19-chloro-2,5-dimethyl-4,16-dioxo-4,5,6,7,9,10,15,16-octahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-7-carboxamide;
[7*R*,16a(17)*Z*]-19-chloro-2,5-dimethyl-4,16-dioxo-*N*-(piperidin-4-yl)-4,5,6,7,9,10,15,16-octahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-7-carboxamide;
[7*R*,16a(17)*Z*]-19-chloro-*N*,2,5-trimethyl-4,16-dioxo-4,5,6,7,9,10,15,16-octahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-7-carboxamide;
[7*R*,16a(17)*Z*]-19-chloro-2,5-dimethyl-4,16-dioxo-*N*-[(3*R*)-pyrrolidin-3-yl]-4,5,6,7,9,10,15,16-octahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-7-carboxamide;
[7*R*,16a(17)*Z*]-19-chloro-*N*,*N*,2,5-tetramethyl-4,16-dioxo-4,5,6,7,9,10,15,16-octahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-7-carboxamide;
[7*R*,16a(17)*Z*]-19-chloro-2,5-dimethyl-7-(4-methylpiperazine-1-carbonyl)-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[10*S*,16a(17)*Z*]-19-chloro-2,5,10-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[16a(17)*Z*]-19-chloro-5-methyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[16a(17)*Z*]-19-chloro-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxathiazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[16a(17)*Z*]-19-chloro-2,5-dimethyl-5,6,7,8,9,10-hexahydro-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxadiazacyclopentadecine-4,16(1*H*,15*H*)-dione;
[16a(17)*Z*]-19-chloro-2,5-dimethyl-6,7,9,10-tetrahydro-12,14-(ethanediylidene)-8λ^6-dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxathiazacyclopentadecine-4,8,8,16(1*H*,5*H*,15*H*)-tetrone;
[16a(17)*Z*]-19-chloro-2,5-dimethyl-6,7,9,10-tetrahydro-12,14-(ethanediylidene)-8λ^4-dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxathiazacyclopentadecine-4,8,16(1*H*,5*H*,15*H*)-trione;

[16a(17)*Z*]-19-chloro-5-methyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxathiazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[16a(17)*Z*]-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,4-*g*:2',3'-*j*][1,4,13]oxathiazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[16a(17)*Z*]-2,5-dimethyl-6,7-dihydro-1*H*,9*H*-12,14-(ethanediylidene)-11λ^6-dipyrrolo[3,4-*g*:2',3'-*j*][1,4,13]oxathiazacyclopentadecine-4,11,11,16(5*H*,10*H*,15*H*)-tetrone;
[16a(17)*Z*]-5-methyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,4-*g*:2',3'-*j*][1,4,13]oxathiazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[16a(17)*Z*]-19-chloro-5-methyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)pyrazolo[4,3-*i*]pyrrolo[3,4-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[16a(17)*Z*]-19-chloro-5-methyl-5,6,7,8,9,10-hexahydro-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxadiazacyclopentadecine-4,16(1*H*,15*H*)-dione;
[16a(17)*Z*]-19-chloro-2,5,8-trimethyl-5,6,7,8,9,10-hexahydro-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxadiazacyclopentadecine-4,16(1*H*,15*H*)-dione;
[16a(17)*Z*]-2,5-dimethyl-4,16-dioxo-4,5,6,7,9,10,15,16-octahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-19-carbonitrile;
[16a(17)*Z*]-19-chloro-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,4-*g*:2',3'-*j*][1,4,13]oxathiazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[16a(17)*Z*]-19-chloro-5-methyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,4-*g*:2',3'-*j*][1,4,13]oxathiazacyclopentadecine-4,16(5*H*,15*H*)-dione;and
[16a(17)*Z*]-19-chloro-5-methyl-6,7-dihydro-1*H*,9*H*-12,14-(ethanediylidene)-11λ^6-dipyrrolo[3,4-*g*:2',3'-*j*][1,4,13]oxathiazacyclopentadecine-4,11,11,16(5*H*,10*H*,15*H*)-tetrone.

19. A pharmaceutical composition comprising at least one compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable excipients.

20. Use of a compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating autoimmune diseases in a subject.